**S1 Table. Clinical patients’ characteristics at baseline**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | **all patients\*** | **nasal carriers** | **non-carriers** | **p-values** | **with**  **exacerbation\*\*** | **without exacerbation** | **p-values** | **with SCVs**  **ever** | **without SCVs** | **p-values** |
| **# of patients** | 195 | 122 (65%)† | 66 (35%) |  | 60 (31%) | 135 (69%) |  | 84 (43%) | 111 (57%) |  |
| **Age (years)**  **Male** | 16  (6-42)  120 (61.54%) | 14.083  (6.02-41.58)  86 (70.5%) | 13.33  (5.82-40.7)  30 (45.5%^) | 0.45‡  0.00075§ | 14.95  (7.23-36.37)  33 (55%) | 13.65  (5.82-41.7)  87 (64.44%) | 0.5182‡  0.2109§ | 15.41  (5.82-41.58)  48 (57.14%) | 13.03  (6.02-40.53)  72 (64.86%) | 0.0066‡  0.2724§ |
| **Ex. panc.suff.‖** | 22 (11%) | 17 | 5 | 0.201§ | 3 (5.08%) | 19 (14.18%) | 0.067§ | 9 (10.8%) | 13 (12.04%) | 0.7978§ |
| **FEV1**  **(% predicted)** | 84.07  (13.18-120.57) | 86.96  (13.18-120.57) | 80.92  (26.35-118.05) | 0.096‡ | 81.64  (26.35-116.82) | 86.27  (13.18-120.57) | 0.1941‡ | 79.48  (13.18-120.57) | 88.56  (30.56-115.19) | 0.0133‡ |
| **BMI-Quantils** | 25%  (0.068%-100%) | 28%  (1%-100%) | 23%  (0.068%-81%) | ns‡ | 26.77%  (1.7%-97.29%) | 24.93%  (0.068%-99.79%) | 0.7740‡ | 23%  (0.068%-92%) | 27%  (4%-100%) | 0.3166‡ |
| **Genotype††**  **F508del homo‡‡**  **F508del hetero§§**  **others** | 173  85 (49%)  40 (23.2%)  48 (27.7%) | 52 (48.1%)  25 (23.1%)  31 (28.7%) | 28 (48.3%)  13 (22.4%)  17 (29.3%) | 0.993§ | 27 (54%)  14 (28%)  9 (18%) | 58 (47.15%)  26 (21.14%)  39 (31.71%) | 0.1764§ | 35 (49.3%)  11 (15.5%)  25 (35.2%) | 49 (49%)  28 (28%)  23 (23%) | 0.079§ |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | **With**  ***S. maltophilia*** | **Without**  ***S. maltophilia*** | **p-values** | **With**  ***A. fumigatus*** | **Without**  ***A. fumigatus*** | **p-values** |
| **# of patients** | 44 | 151 |  | 60 (31%) | 135 (69%) |  |
| **Age (years)**  **Male** | 15.78  (7.33-36.37)  20 (45.45%) | 13.51  (5.82-41.58)  100 (66.23%) | 0.0847‡  0.0127§ | 18.10  (8.99-41.58)  34 (56.67%) | 12.85  (5.82-40.70)  86 (63.7%) | <0.0001‡  0.3512§ |
| **Ex. panc.suff.‖** | 2 (4.55%) | 20 (13.61%) | 0.0986§ | 7 (11.86%) | 15 (11.36) | 0.9202§ |
| **FEV1**  **(% predicted)** | 80.05  (38.96-120.57) | 85.89  (13.18-118.05) | 0.2071‡ | 80.41  (37.56-120.57) | 85.60  (13.18-118.05) | 0.2698‡ |
| **BMI-Quantils** | 23%  (5%-92%) | 25%  (0.068%-100%) | 0.8861‡ | 23%  (1%-97%) | 27%  (0.068%-100%) | 0.2332‡ |
| **Genotype††**  **F508del homo‡‡**  **F508del hetero§§**  **others** | 171  20 (52.63%)  8 (21.05%)  10 (26.32%) | 64 (48.12%)  31 (23.31%)  38 (28.57%) | 0.8861§ | 171  26 (49.06%)  12 (22.64%)  15 (28.3%) | 58 (49.15%)  27 (22.88%)  33 (27.97%) | 0.9988§ |

\*Age, FEV1, BMI and exacerbation numbersare reported as median(range), respectively. Exocrine pancreatic sufficiency and genotype are reported as absolute frequencies (relative frequencies).

†patients with only one or two nasal swabs were excluded from the analysis (n=7)

‡Mann-Whitney U-test

§Chi-Quadrat test

‖exocrine pancreatic sufficiency

\*\*percentage of exacerbations as indicated in CRFs calculated in percentage for every patient with the range

††*Cftr* genotype of patients available

‡‡F508del homozygous

§§F508del heterozygous